Discover
Lynparza (olaparib) / Merck (MSD), AstraZenecaSOLI: Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer (clinicaltrials.gov) - Apr 1, 2020 - P4; N=200; Not yet recruiting; Sponsor: AstraZeneca
DPX-Survivac (EMD 640744) / IMV Inc; Keytruda (pembrolizumab) / Merck (MSD)IMV Inc. announces fourth quarter and full year 2019 financial and operational results (Businesswire) - Mar 30, 2020 - "SPiReL is an investigator-initiated Phase 2 study evaluating DPX-Survivac and CPA in combination with Keytruda® (pembrolizumab) in r/r DLBCL....The study remains ongoing, with preliminary topline results expected in 2020....The Basket Trial is an open label, multi-center Phase 2 study, evaluating the safety and efficacy of DPX-Survivac and CPA in combination with Keytruda® across five cohorts of patients with bladder cancer, liver cancer (hepatocellular carcinoma), ovarian cancer (with and without CPA), NSCLC and tumors shown to be positive for the microsatellite instability high (MSI-H) biomarker....In the context of the COVID-19 pandemic, IMV expects to report preliminary topline clinical results on several of the solid tumor indications later in 2020."
Keytruda (pembrolizumab) / Merck (MSD)A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 31, 2020 - P1/2; N=82; Completed; Sponsor: Array BioPharma; Active, not recruiting --> Completed; Trial completion date: Apr 2020 --> Oct 2019; Trial primary completion date: Apr 2020 --> Oct 2019
